HT Welcomes the Scientific Community with the New External Seminar Series
We are pleased to announce the launch of the Human Technopole External Seminar Series, an initiative dedicated to bringing leading researchers from around the world on campus. These scientists, working in various life sciences disciplines, will share their latest research and insights with the HT and external scientific community.
Starting from 12 September with James Briscoe, with two dates in 2024, and continuing throughout 2025, Human Technopole will host talks by internationally renowned scientists who are making significant contributions in various fields, including genomics, neurogenomics, structural biology, computational biology, health data science, biophysical modelling, and molecular cell biology.
These seminars, free and open in presence to everyone, aim to create a space for intellectual exchange that bridges different areas of expertise, contributing to the broader scientific discourse and driving innovation in the study of human health and disease.
Each seminar will take place from 16.00 to 17.00 CET at the Human Technopole Auditorium in Milan. To participate, registration is required via the forms that will be made available.
Calendar:
- 12 September 2024 – James Briscoe, The Francis Crick Institute
- 7 November 2024 – Julia Mahamid, EMBL Heidelberg
- 3 April 2025 – Kai Simons, Max Planck Institute of Molecular Cell Biology and Genetics
- 15 May 2025 – Julie Theriot, University of Washington
- 5 June 2025 – Soumya Raychaudhuri, Harvard Medical School
- 12 June 2025 – Elena Conti, Max Planck Institute of Biochemistry
- 2 October 2025 – Francesca Peri, University of Zurich
- 6 November 2025 – Erin Schuman, Max Planck Institute for Brain Research
- 13 November 2025 – Yifan Cheng, University of California, San Francisco
MORE INFO & REGISTRATION
Share:
You could also like:
-
How colorectal cancer escapes from the immune system early on
An international study co-led by scientists from Human Technopole reveals that colorectal tumours use both genetic and epigenetic strategies to evade immune detection almost immediately after they transform into cancerous. The results, published in Nature Genetics, challenge previous notions that immune evasion occurs gradually over time.
-
Human Technopole awarded grant to create 3D models of rare brain cancer
Human Technopole researchers Nereo Kalebic and Blagoje Soskic have been awarded $1,319,010 by the Gilbert Family Foundation (GFF) through the Next-Generation NF1 Models Initiative. Their funded project “Assembloid Platform to Model Cellular Interactions Driving NF1 Glioma Pathology” focuses on developing the first 3D cell culture model of Neurofibromatosis type 1 (NF1), a genetic cancer predisposition syndrome that affects the central and peripheral nervous systems and increases the risk of high-grade gliomas.
-
Exploring nuclear organisation with the GRADMAP project
Meet Emily Georgiades, Postdoc in the Bienko Group (Genomics), who has been awarded a prestigious Marie Skłodowska-Curie Actions Postdoctoral Fellowship from the European Union for her project “GRADMAP: Multi-dimensional mapping of lineage-specific transcription factors through time and space”. The grant will cover a two-year period with 193.643 euros.
-
The role of adducins in the development of the cerebral cortex
Human Technopole researchers show that adducin proteins regulate morphology, proliferation, and fate of neural progenitor cells, sustaining the expansion of the mammalian neocortex. The findings, which offer fresh insights into the molecular logic behind neurogenesis, are published in Cell Reports.
-
FRRB funds the Glastonbury Group to study the immune landscape of pancreatic cancer
The Glastonbury Group at Human Technopole has been awarded a competitive grant as part of the “From Bed To Bench: the way to innovation” funding programme promoted by the Fondazione Regionale per la Ricerca Biomedica (FRRB). The study, funded with 2.000.000 euros, 600.000 of which will go to the Glastonbury group directly, will begin in late 2025 and run for 3 years.